Multivariate analyses of the sorafenib, placebo, and all-patient cohorts to identify factors independently prognostic for OS in patients with HCC
| Placebo cohort | Sorafenib cohort | All-patient cohort | ||||
|---|---|---|---|---|---|---|
| Baseline factor | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) |
| Treatment (sorafenib vs. placebo) | NA | — | NA | — | 0.041 | 0.78 (0.61–0.99) |
| ECOG PS (0 vs. >0) | NS | — | NS | — | 0.016 | 1.36 (1.06–1.75) |
| AFP (≤ vs. >200 ng/mL) | 0.007 | 1.58 (1.13–2.21) | 0.015 | 1.57 (1.09–2.26) | 0.001 | 1.49 (1.17–1.89) |
| MVI (present vs. absent) | 0.0003 | 1.88 (1.34–2.66) | 0.005 | 1.74 (1.19–2.55) | <0.0001 | 1.81 (1.43–2.32) |
| EHS (present vs. absent) | NS | — | 0.016 | 1.60 (1.09–2.34) | NS | — |
| Alkaline phosphatase (≤ vs. >median) | 0.013 | 1.56 (1.10–2.22) | 0.002 | 1.82 (1.26–2.63) | 0.0003 | 1.59 (1.24–2.04) |
| s-c-KIT (≤ vs. >11.3 ng/mL) | NS | — | 0.004 | 0.56 (0.38–0.83) | NS | — |
| HGF (≤ vs. >3,279.1 pg/mL) | NS | — | 0.017 | 1.69 (1.10–2.60) | NS | — |
| VEGF (≤ vs. >101.9 pg/mL) | 0.002 | 1.97 (1.28–3.04) | NS | — | 0.015 | 1.48 (1.08–2.03) |
| Ang2 (≤ vs. >6,043.5 pg/mL) | 0.002 | 1.84 (1.25–2.70) | 0.034 | 1.59 (1.04–2.43) | 0.001 | 1.58 (1.20–2.07) |
NOTE: Analyses included the following baseline variables: all biomarker values, ECOG PS, AFP, macroscopic vascular invasion (MVI), extrahepatic spread (EHS), albumin score, alkaline phosphatase, bilirubin score, prothrombin time, presence of ascites, and, for the all-patient cohort analysis, treatment group. Factors with P < 0.05 in one or more of the analyses are shown.
Abbreviations: NA, not applicable; NS, not significant (P > 0.05).